Posted by Michael Wonder on 14 Oct 2024
Enhertu approved in China as first HER2 directed therapy for patients with HER2 mutant metastatic non-small cell lung cancer
14 October 2024 - Approval based on DESTINY-Lung02 and DESTINY-Lung05 results which showed Enhertu demonstrated clinically meaningful efficacy in previously treated patients.
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic non-small cell lung cancer whose tumours have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy.
